LSU Health Shreveport begins enrollment in COVID-19 vaccine study

829

Shreveport, LA – LSU Health Shreveport has begun enrollment in the Pfizer-sponsored COVID-19 vaccine study. This is a randomized, placebo-controlled trial of an mRNA vaccine to prevent illness due to the SARS-CoV2 virus. The vaccine will be administered by injection. Further details of the study can be found at: https://clinicaltrials.gov.

LSU Health Shreveport discoveries were licensed earlier this year by global biopharma firm BioNTech and serve as a key building block of Pfizer’s mRNA vaccine currently in Phase 2/3 safety and efficacy clinical study.

Adults 18-85 years old who are not pregnant, in good general health and have not been previously diagnosed with COVID-19 can participate in the study once approved by the principal investigator. An assessment on each individuals risk for contracting the COVID-19 includes understanding one’s type of work, lifestyle and all medical conditions. All those interested in being a part of this vaccine trial should promptly complete the COVID-19 Vaccine Interest Survey. The survey can be found on the LSU Health Shreveport website at: lsuhs.edu/coronavirus.

Currently, there are no approved vaccines available to prevent COVID-19. This disease has spread across the world. This COVID-19 vaccine study will enroll up to 30,000 adults, and each person involved plays a powerful role. Joining a clinical trial is an important and personal decision.

“LSU Health Shreveport is excited to continue our impact on the COVID-19 pandemic by serving as a site for this Pfizer-sponsored vaccine trial. Having our discoveries play a key role in the availability of this worldwide vaccine trial is another example of the strength of our research faculty”, stated Dr. G. E. Ghali, Chancellor, LSU Health Shreveport.

The principal investigator for this vaccine trial is John Vanchiere MD PhD, Professor of Infectious Disease and Pediatrics and a NIH funded researcher. He is currently serving as the leader of the COVID -19 Strike Team providing testing in 98% of Region 7 nursing homes and in other strategic communities.